Medtronic study shows benefits of evidence-based heart failure therapy

Medtronic has published data from Improve HF, a clinical study that showcases the advantages of evidence-based medication and device therapy for heart failure patients.

The application of evidence-based performance improvement interventions in outpatient settings was shown to deliver equivalent improvements in the care of heart failure patients across all races and ethnicities during the trial.

Interventions included clinical decision support tools and patient chart reviews with performance feedback, as well as structured improvement strategies such as assessment forms and patient education materials.

The US-based study involved more than 7,600 patients and also demonstrated that evidence-based programmes provided improved patient survival rates over 24 months.

Dr David Steinhaus, vice-president and general manager for heart failure and medical director for the cardiac rhythm disease management business at Medtronic, said: "This research represents a significant milestone demonstrating our commitment to innovation in identifying the best, most clinically advanced solutions for ensuring patient quality of care."

This comes after the firm published trial data last week showing the long-term benefits offered to coronary artery disease patients by drug-eluting stents.